Personalis reported a 30% year-over-year revenue rise in Q2, driven by growth in pharma testing services and an increase in covered clinical lung cancer and immune-oncology monitoring. The company also said Medicare clearance expanded adoption for its NeXT Personal assay in monitoring treatment response for defined breast cancer subgroups. Personalis’ quarter showed clinical test volume more than doubling year over year, and it disclosed increased R&D spending alongside higher operating costs. Net loss widened versus the prior year period, but cash and short-term investments remained substantial. The financial update comes as Personalis awaits its $1.5 billion acquisition by Tempus AI, keeping focus on post-close growth execution and expanding payer and Medicare coverage as key demand drivers.